Publications

Miller J, Cuby J, Hall SM, Stitzer M, Kushel M, Appiah D, Vijayaraghavan M. Corrigendum to "Tobacco use behaviors and views on engaging in clinical trials for tobacco cessation among individuals who experience homelessness" [Contemporary Clinic. Trials Commun. 32 (2023) 101094]. Contemporary Clinical Trials Communications. 2025. PMID: 40727927

Jagannath S, Martin TG, Lin Y, Cohen AD, Raje N, Htut M, Deol A, Agha M, Berdeja JG, Lesokhin AM, Liegel JJ, Rossi A, Lieberman-Cribbin A, Usmani SZ, Dhakal B, Parekh S, Li H, Wang F, Montes de Oca R, Plaks V, Sun H, Banerjee A, Schecter JM, Lendvai N, Madduri D, Lengil T, Zhu J, Koneru M, Akram M, Patel N, Costa Filho O, Jakubowiak AJ, Voorhees PM. Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40459151

Soragni A, Knudsen ES, O'Connor TN, Tognon CE, Tyner JW, Gini B, Kim D, Bivona TG, Zang X, Witkiewicz AK, Goodrich DW, Jiang D, Gammon ST, Willey CD, Boutros PC, Sandulache VC, Osman AA, Myers JN, Mehla K, Singh PK, Chan KS, Gao H, Marathe H, National Cancer Institute (NCI) Acquired Resistance to Therapy Network (ARTNet). Acquired resistance in cancer: towards targeted therapeutic strategies. Nature reviews. Cancer. 2025. PMID: 40461793

Jonas BA, Fisch SC, Curtin PT, Schiller GJ, Jeyakumar D, Tzachanis D, Bejar R, Qi L, Wieduwilt MJ, Tuscano JM, Damon L, Logan AC, University of California Hematologic Malignancies Consortium. A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503). Leukemia Research. 2025. PMID: 40479857

He J, Tsuboi M, Weder W, Chen KN, Hochmair MJ, Shih JY, Lee SY, Lee KY, Nhung NV, Saeteng S, Liu L, Xing L, Gia NH, Murakami S, Han Y, Saavedra MP, Yoon SH, Teixeira CHA, Escriu C, Martinez-Marti A, Blakely CM, Yatabe Y, Dacic S, Rukazenkov Y, Huang X, Dayal A, Chaft JE, NeoADAURA Investigators. Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40454705

García-Estévez L, Bardia A, Rugo HS, Carey LA, Diéras VC, Loibl S, Piccart M, Gianni L, Kalinsky K, O'Shaughnessy J, Hurvitz SA, Harting E, Valdez T, Phan S, Lai C, Cortés J. The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study. ESMO open. 2025. PMID: 40460679

Duan Z, Shi M, Kumaraswamy A, Lin D, Khokhani D, Wang Y, Zhang C, Flores D, Rodansky E, Swaim OA, Storck WK, Beck HN, Patel RA, Sayar E, Hanratty BP, Xue H, Dong X, Maylin ZR, Wan R, Quigley DA, Sjöström M, Hu YM, Zhao F, Xia Z, Cheng S, Yu X, Feng FY, Zhang L, Aggarwal R, Small EJ, Ravikumar V, Rao A, Bedi K, Lee JK, Morrissey C, Coleman I, Nelson PS, Corey E, Udager AM, Rebernick RJ, Cieslik MP, Chinnaiyan AM, Yates JA, Haffner MC, Wang Y, Alumkal JJ. PROX1 is an early driver of lineage plasticity in prostate cancer. The Journal of clinical investigation. 2025. PMID: 40454483

Kennedy VE, Roy R, Peretz CAC, Koh A, Tran E, Smith CC, Olshen AB. SNACS: a tool for demultiplexing single-cell DNA sequencing data. Bioinformatics (Oxford, England). 2025. PMID: 40471703

Rueda-Lara M, Barrera I, Komanduri KV, Pereira D, Lekakis L, Wang TP, Jimenez AM, Beitinjaneh A, Holtzman NG, Green DJ, Goodman M, Benjamin CL, Spiegel J, Lehardy EN, Antoni MH, Goldstein H, Harvey PD, Wright BJ. Psychosocial correlates of failure to complete hematopoietic stem cell transplants in a diverse population. Bone marrow transplantation. 2025. PMID: 40456936

Christopher Johns, Hala Borno, Samuel L. Washington, Wesley Robinson, Miriam Perales, Rahul Raj Aggarwal, Rohit Bose, Jonathan Chou, Arpita Desai, Kelly N. Fitzgerald, Terence W. Friedlander, Vadim S Koshkin, Ivan de Kouchkovsky, Elizabeth Pan, Eric J. Small, Noah Spector Younger, Xiaolin Zhu, Franklin W. Huang, Daniel H. Kwon. Development of a culturally tailored educational tool designed to increase access to somatic testing among Black men with metastatic prostate cancer (mPCa). Journal of Clinical Oncology. 2025. PMID:

Tanya Jindal, Emily Wu, Sara Topalovic, Nana Shakhnazaryan, Sylvia Zhang, Hala Borno. Enhancing clinical trial site efficiency and unlocking patient access to clinical trials using technology-enabled pre-screening. Journal of Clinical Oncology. 2025. PMID:

Kevin Kayvan Zarrabi, Tolulope Tosin Adeyelu, Andrew Elliott, Daniel M. Geynisman, David Yoonsuk Oh, Carissa E. Chu, Rana R. McKay, Nicholas Zorko, Emmanuel S. Antonarakis, Lucia Languino, Pedro C. Barata, Daniel Costin Danila, Norm Smith, William Kevin Kelly. Molecular characterization of STEAP1 and -2 in advanced prostate cancer. Journal of Clinical Oncology. 2025. PMID:

Aishwarya Nene, Mark Bridge, Rahul Raj Aggarwal, David Yoonsuk Oh, Lawrence Fong, Bridget P. Keenan. Neutrophil-to-lymphocyte ratio as a predictor of response and toxicity in T-cell engager therapy for solid tumors. Journal of Clinical Oncology. 2025. PMID:

Riely GJ, Wood DE, Loo BW, Aisner DL, Akerley W, Bauman JR, Bharat A, Chang JY, Chirieac LR, DeCamp M, Desai A, Dilling TJ, Dowell J, Durm GA, Gettinger S, Grotz TE, Gubens MA, Juloori A, Lackner RP, Lanuti M, Lin J, Lovly CM, Maldonado F, Morgensztern D, Mullikin TC, Ng T, Owen D, Owen DH, Patel SP, Patil T, Polanco PM, Riess J, Shapiro TA, Singh AP, Stevenson J, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory K, Hang L. Thymomas and Thymic Carcinomas, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 2025. PMID: 40499586

Zandberg DP, Allred JB, Rosenberg AJ, Kaczmar JM, Swiecicki P, Julian RA, Poklepovic AS, Bauman JR, Phan MD, Saba NF, Rivera E, Rowland K, Davar D, Cordes J, Ho AL, Zhang M, Berg SA, Munster PN, Schwartz GK. Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40448574

Li H, Melnyk JE, Fu BXH, Shrestha R, Zhang M, Sjöström M, Feng S, Anderson JA, Han W, Chesner LN, Shin HJ, Farsh T, Suarez HJ, Nath S, Chou J, Das R, Egusa EA, Zhu J, Winters A, Maheshwari A, Hua JT, Alshalalfa M, Chen WS, Calvert M, Davicioni E, Kishishita A, Barpanda A, Liu T, Wiita AP, Stohr BA, Siddiqui J, Huang B, Small EJ, Shokat KM, Nelson P, Quigley DA, Wasmuth EV, Gilbert LA, Feng FY. Genome-wide CRISPR screens identify PTGES3 as a novel AR modulator. bioRxiv : the preprint server for biology. 2025. PMID: 40501535

Correy GJ, Rachman MM, Togo T, Gahbauer S, Doruk YU, Stevens MGV, Jaishankar P, Kelley B, Goldman B, Schmidt M, Kramer T, Radchenko DS, Moroz YS, Ashworth A, Riley P, Shoichet BK, Renslo AR, Walters WP, Fraser JS. Exploration of structure-activity relationships for the SARS-CoV-2 macrodomain from shape-based fragment linking and active learning. Science advances. 2025. PMID: 40435250

Pan D, Kumar A, Lipof JJ, Chung A, Wolf JL, Martin TG, Arora S, Sayre PH, Chari A. Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review. Expert opinion on investigational drugs. 2025. PMID: 40425184

Kawasaki K, Salehi S, Zhan YA, Chen K, Lee JH, Salataj E, Zhong H, Manoj P, Kinyua D, Mello BP, Sridhar H, Tischfield SE, Linkov I, Ceglia N, Zatzman M, Havasov E, Shah NJ, Meng F, Loomis B, Bhanot UK, Redin E, de Stanchina E, Hamard PJ, Koche RP, McPherson A, Quintanal-Villalonga Á, Shah SP, Massagué J, Rudin CM. FOXA2 promotes metastatic competence in small cell lung cancer. Nature communications. 2025. PMID: 40419484

Menzies AM, Long GV, Kohn A, Tawbi H, Webe J, Flaherty K, McArthur GA, Ascierto PA, Pfluger Y, Lewis K, Tsai KK, Hamid O, Prenen H, Fein L, Wang E, Guenzel C, Zhang F, Kleh JF, di Pietro A, Davies MA. A plain language summary of POLARIS: a study to look at different doses of encorafenib plus binimetinib for people with BRAF V600-mutant melanoma with brain metastasis. Future oncology (London, England). 2025. PMID: 40418081